Search

everythinglearnresearchcommunity

for

Search:↓

Dupilumab and ustekinumab are promising treatments for alopecia areata, showing significant hair regrowth.

Dupilumab may worsen Alopecia Areata in some males but improve it in some females, suggesting personalized treatment is needed.

The choice between belimumab and anifrolumab depends on the specific symptoms of the patient's lupus.

Lupus patients in Ghana face healthcare challenges, and the Oyemam Autoimmune Foundation is working to improve awareness and support.

Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.

Anifrolumab improves quality of life and reduces steroid use in SLE patients.

Anifrolumab improves quality of life and reduces steroid use in lupus patients.

The choice between belimumab and anifrolumab for treating lupus depends on the patient's specific symptoms.

Selective immunotherapies like anifrolumab and belimumab are more effective for treating systemic lupus erythematosus than traditional drugs.

Anifrolumab effectively improved symptoms and reduced steroid use in Japanese patients with systemic lupus erythematosus.

INTASYL is a promising, adaptable RNAi technology for treating skin cancers.

People with lupus in Mauritius face many challenges and need more support and understanding.

Dupilumab is being tested for many new skin, respiratory, and gastrointestinal conditions.

Anifrolumab treatment improves quality of life and reduces disease activity and steroid use in SLE patients.

Belimumab effectively controls SLE disease activity and reduces steroid use.

SLE is rare in Uganda but often has complications and overlaps with rheumatoid arthritis.

Dupilumab improved severe atopic dermatitis in a patient who didn't respond to other treatments.

Uveal melanoma is hard to treat when it spreads, but a new drug, tebentafusp, helps patients live longer.

Anifrolumab may help improve symptoms in patients with overlapping autoimmune diseases.

Anifrolumab effectively improved lupus headaches in a patient unresponsive to other treatments.

Belimumab reduces disease activity, steroid use, and flares in lupus patients.

Ixekizumab helps improve life quality, physical ability, and work performance in patients with psoriatic arthritis who haven't used biologic drugs before.

Anifrolumab helped some lupus patients reduce steroid use, but safety concerns remain.

Belimumab effectively reduces disease activity in lupus patients, regardless of initial serologic status.

A medication for skin rash also unexpectedly treated hair loss in a patient.

Lupus severely affects daily life, work, and mental health, with many experiencing frequent flares and medication side-effects.

The drug Olumiant is now approved to treat severe hair loss from alopecia and can also be used for some hospitalized COVID-19 patients.

New partnerships, clinical trials, and drug approvals marked progress in therapeutic delivery in July 2018.

Maltadya Tail might be a good, affordable, and easy-to-use treatment for hair loss.

The FDA approved Litfulo® for treating severe alopecia areata in people aged 12 and older.